Changes in Inflammatory Cytokines in Responders and Non-Responders to TNFα Inhibitor and IL-17A Inhibitor: A Study Examining Psoriatic Arthritis Patients
This study aimed to examine the changes in biomarker levels in responders and non-responders to tumor necrosis factor alpha inhibitor (TNFi) and interleukin-17A inhibitor (IL-17Ai) in psoriatic arthritis (PsA) patients over a 4-month period after treatment initiation. A total of 68 PsA patients init...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-03-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/25/5/3002 |
| _version_ | 1797264375065608192 |
|---|---|
| author | Marie Skougaard Magnus Friis Søndergaard Sisse Bolm Ditlev Lars Erik Kristensen |
| author_facet | Marie Skougaard Magnus Friis Søndergaard Sisse Bolm Ditlev Lars Erik Kristensen |
| author_sort | Marie Skougaard |
| collection | DOAJ |
| description | This study aimed to examine the changes in biomarker levels in responders and non-responders to tumor necrosis factor alpha inhibitor (TNFi) and interleukin-17A inhibitor (IL-17Ai) in psoriatic arthritis (PsA) patients over a 4-month period after treatment initiation. A total of 68 PsA patients initiating either TNFi, IL-17Ai, or methotrexate treatment were included. Blood plasma and clinical outcome measures were collected adjacent to treatment initiation and after four months. A commercially available multiplex immunoassay was included to evaluate 54 biomarkers. Mean changes were used to evaluate change over time. A statistically significant decrease in pro-inflammatory cytokines IL-6 (log-transformed mean change −0.97, 95%CI −4.30; 2.37, [<i>p</i> = 0.032]) and an increase in anti-inflammatory IL-10 (0.38, 95%CI 1.74; 2.50 [<i>p</i> = 0.010]) were seen in TNFi responders. Meanwhile, a statistically significant increase in the target cytokine IL-17A was seen in both IL-17Ai responders (2.49, 95%CI −1.84; 6.85 [<i>p</i> = 0.031]) and non-responders (2.48, 95%CI −1.46; 6.41 [<i>p</i> = 0.001]). This study demonstrated differing changes in cytokine levels when comparing treatment responders and non-responders, highlighting the need to improve the understanding of the different immune response mechanisms explaining different responses to medical treatment in PsA patients. |
| first_indexed | 2024-04-25T00:27:54Z |
| format | Article |
| id | doaj.art-9b28a3528af7446daa31a231faa57210 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-04-25T00:27:54Z |
| publishDate | 2024-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-9b28a3528af7446daa31a231faa572102024-03-12T16:47:12ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672024-03-01255300210.3390/ijms25053002Changes in Inflammatory Cytokines in Responders and Non-Responders to TNFα Inhibitor and IL-17A Inhibitor: A Study Examining Psoriatic Arthritis PatientsMarie Skougaard0Magnus Friis Søndergaard1Sisse Bolm Ditlev2Lars Erik Kristensen3The Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, 2000 Frederiksberg, DenmarkCopenhagen Center for Translational Research, Copenhagen University Hospital Bispebjerg and Frederiksberg, Bispebjerg Bakke 23, 2400 Copenhagen, DenmarkCopenhagen Center for Translational Research, Copenhagen University Hospital Bispebjerg and Frederiksberg, Bispebjerg Bakke 23, 2400 Copenhagen, DenmarkThe Parker Institute, Copenhagen University Hospital Bispebjerg and Frederiksberg, Nordre Fasanvej 57, 2000 Frederiksberg, DenmarkThis study aimed to examine the changes in biomarker levels in responders and non-responders to tumor necrosis factor alpha inhibitor (TNFi) and interleukin-17A inhibitor (IL-17Ai) in psoriatic arthritis (PsA) patients over a 4-month period after treatment initiation. A total of 68 PsA patients initiating either TNFi, IL-17Ai, or methotrexate treatment were included. Blood plasma and clinical outcome measures were collected adjacent to treatment initiation and after four months. A commercially available multiplex immunoassay was included to evaluate 54 biomarkers. Mean changes were used to evaluate change over time. A statistically significant decrease in pro-inflammatory cytokines IL-6 (log-transformed mean change −0.97, 95%CI −4.30; 2.37, [<i>p</i> = 0.032]) and an increase in anti-inflammatory IL-10 (0.38, 95%CI 1.74; 2.50 [<i>p</i> = 0.010]) were seen in TNFi responders. Meanwhile, a statistically significant increase in the target cytokine IL-17A was seen in both IL-17Ai responders (2.49, 95%CI −1.84; 6.85 [<i>p</i> = 0.031]) and non-responders (2.48, 95%CI −1.46; 6.41 [<i>p</i> = 0.001]). This study demonstrated differing changes in cytokine levels when comparing treatment responders and non-responders, highlighting the need to improve the understanding of the different immune response mechanisms explaining different responses to medical treatment in PsA patients.https://www.mdpi.com/1422-0067/25/5/3002psoriatic arthritiscytokinebDMARDsTNFαIL-17A |
| spellingShingle | Marie Skougaard Magnus Friis Søndergaard Sisse Bolm Ditlev Lars Erik Kristensen Changes in Inflammatory Cytokines in Responders and Non-Responders to TNFα Inhibitor and IL-17A Inhibitor: A Study Examining Psoriatic Arthritis Patients International Journal of Molecular Sciences psoriatic arthritis cytokine bDMARDs TNFα IL-17A |
| title | Changes in Inflammatory Cytokines in Responders and Non-Responders to TNFα Inhibitor and IL-17A Inhibitor: A Study Examining Psoriatic Arthritis Patients |
| title_full | Changes in Inflammatory Cytokines in Responders and Non-Responders to TNFα Inhibitor and IL-17A Inhibitor: A Study Examining Psoriatic Arthritis Patients |
| title_fullStr | Changes in Inflammatory Cytokines in Responders and Non-Responders to TNFα Inhibitor and IL-17A Inhibitor: A Study Examining Psoriatic Arthritis Patients |
| title_full_unstemmed | Changes in Inflammatory Cytokines in Responders and Non-Responders to TNFα Inhibitor and IL-17A Inhibitor: A Study Examining Psoriatic Arthritis Patients |
| title_short | Changes in Inflammatory Cytokines in Responders and Non-Responders to TNFα Inhibitor and IL-17A Inhibitor: A Study Examining Psoriatic Arthritis Patients |
| title_sort | changes in inflammatory cytokines in responders and non responders to tnfα inhibitor and il 17a inhibitor a study examining psoriatic arthritis patients |
| topic | psoriatic arthritis cytokine bDMARDs TNFα IL-17A |
| url | https://www.mdpi.com/1422-0067/25/5/3002 |
| work_keys_str_mv | AT marieskougaard changesininflammatorycytokinesinrespondersandnonresponderstotnfainhibitorandil17ainhibitorastudyexaminingpsoriaticarthritispatients AT magnusfriissøndergaard changesininflammatorycytokinesinrespondersandnonresponderstotnfainhibitorandil17ainhibitorastudyexaminingpsoriaticarthritispatients AT sissebolmditlev changesininflammatorycytokinesinrespondersandnonresponderstotnfainhibitorandil17ainhibitorastudyexaminingpsoriaticarthritispatients AT larserikkristensen changesininflammatorycytokinesinrespondersandnonresponderstotnfainhibitorandil17ainhibitorastudyexaminingpsoriaticarthritispatients |